Please read and agree to the terms and conditions of this site.
@xconomy.com 5 years ago
Delivery Robots in Big D, Rodriguez Leaves the Station, & More TX Tech
@xconomy.com 5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com 5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com 5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com 5 years ago
Renovia Raises $42M to Back Digital Treatment for Incontinence
@xconomy.com 5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com 5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com 5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com 5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@xconomy.com 5 years ago
Boston Scientific Continues M&A Streak with $202M Deal for Cryterion
@xconomy.com 5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com 5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com 6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com 6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
@xconomy.com 6 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details
@xconomy.com 6 years ago
Histogen Treatment for Female Hair Loss Cleared for Clinical Testing